Bacillus Calmette-Guérin Strain Differences Have an Impact on Clinical Outcome in Bladder Cancer Immunotherapy

noticia |

Rentsch C.A., Birkhäuser F.D., Biot C., Gsponer J.R., Bisiaux A., Wetterauer C., Lagranderie M., Marchal G., Orgeur M., Bouchier C., Bachmann A., Ingersoll M.A., Brosch R., Albert M.L., Thalmann G.N.

European Urology 2014

Background: Whether the commonly used bacillus Calmette-Guérin (BCG) strains Connaught and Tice confer different treatment responses in non-muscle-invasive bladder cancer (NMIBC) is unknown. Objectives: To compare clinical efficacy, immunogenicity, and genetics of BCG Connaught and Tice. Design, setting, and participants: A prospective randomized single-institution trial with treatment of 142 high-risk NMIBC patients with BCG Connaught or Tice. Intervention: Patients were randomized to receive six instillations of BCG Connaught or Tice. For experimental studies, BCG strains were compared in C57Bl/6 mice. Bladders and lymphoid tissues were analyzed by cytometry and the latter cultivated to detect live BCG. BCG genomic DNA was sequenced and compared with reference genomes…(ver más)

Valora esta noticia

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...